SENSOR-AUGMENTED INSULIN PUMP THERAPY WITH AUTOMATED INSULIN SUSPENSION IN HIGH RISK TYPE 1 DIABETES PATIENTS LIKELY COST EFFECTIVE

Published Sep 24, 2014
Perth, Australia – Researchers from the University of Western Australia have conducted a modelling study indicating sensor-augmented insulin pump therapy with Low Glucose Suspend functionality (SAPT-LGS) is a cost-effective alternative to standard pump therapy with self-monitoring of blood glucose, for type 1 diabetes patients with impaired hypoglycaemia awareness. This economic evaluation, published in Value in Health, builds upon clinical evidence[i] showing significantly reduced incidence of severe hypoglycaemia and improved quality of life utility scores in these high risk patients when treated with SAPT-LGS. When combined with estimated medical resource use and associated costs over a six-month period, SAPT-LGS was estimated to be cost-effective in the Australian health care setting. “Given the high clinical focus to prevent hypoglycaemic episodes in these vulnerable patients, our findings support the use of this new technology.  Not only is this an effective treatment to reduce potentially life-threatening hypoglycemia, but it is likely cost-effective for the health care system. It will be the responsibility of health care funders and policy makers to ensure the availability of this therapy to these at risk patients,” said co-author Professor Tim Jones, MD, DCH, FRACP from the School of Paediatrics and Child Health and Telethon Institute of Child Health Research at the University of Western Australia. The full study, “A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes,” is published in Value in Health.

[i] Ly T et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycaemia in patients with type 1 diabetes: A randomised Clinical Trial. JAMA 2013; 310(12):1240-1247  

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×